{"id":"W3213113842","doi":"10.1136/ijgc-2021-003017","title":"Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001","year":2021,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"National Cancer Institute; Merck Sharp and Dohme","keywords":"Medicine; Lenvatinib; Pembrolizumab; Internal medicine; Oncology; Endometrial cancer; Carboplatin; Chemotherapy; Cancer; Immunotherapy; Thyroid cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004596586,0.003275066,0.004662103,0.000680412,0.0009382688,0.001945089,0.002046105,0.003326357,0.01133163],"category_scores_gemma":[0.003761613,0.001277211,0.002959544,0.0006643127,0.002269502,0.002256671,0.0007167534,0.007008477,0.002386752],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001689733,"about_ca_system_score_gemma":0.003137999,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001613097,"about_ca_topic_score_gemma":0.003632261,"domain_scores_codex":[0.9984179,0.0009015296,0.00006422595,0.0002543048,0.0001226616,0.0002393563],"domain_scores_gemma":[0.997239,0.0006825524,0.000692215,0.0002743358,0.0002016492,0.0009102813],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9816226,0.01141676,0.0002629808,0.0002337494,0.0005053504,0.00002535133,0.00003550945,0.0002134447,0.001214003,0.00006502746,0.0007889637,0.00361621],"study_design_scores_gemma":[0.9586095,0.03980275,0.0005090109,0.00001247942,0.0001501367,0.00001833155,0.00001034163,0.0003090642,0.0001517419,0.0001129222,0.0003041203,0.000009557007],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9579319,0.003520186,0.001584511,0.002120236,0.001489329,0.02485544,0.004186136,0.0004760904,0.003836133],"genre_scores_gemma":[0.9341258,0.002616978,0.005263379,0.00504204,0.001188827,0.04090291,0.004117443,0.0001155175,0.006626995],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01133163,"threshold_uncertainty_score":0.03790802,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1565356181272292,"score_gpt":0.4659563725118488,"score_spread":0.3094207543846196,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}